Simultaneous quantification of nirmatrelvir and ritonavir by LC-MS/MS in patients treated for COVID-19

Nirmatrelvir is an antiviral agent active against SARS-CoV-2, the virus causing the pandemic disease COVID-19. It is administrated in combination with the protease inhibitor ritonavir, which acts in case of COVID-19 mainly as enzyme blocking agent preventing the premature metabolic elimination of ni...

Descripción completa

Detalles Bibliográficos
Autores principales: Martens-Lobenhoffer, Jens, Böger, Corinna R., Kielstein, Jan, Bode-Böger, Stefanie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576249/
https://www.ncbi.nlm.nih.gov/pubmed/36274268
http://dx.doi.org/10.1016/j.jchromb.2022.123510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576249/
https://www.ncbi.nlm.nih.gov/pubmed/36274268
http://dx.doi.org/10.1016/j.jchromb.2022.123510

Ejemplares similares